PBM FAIR Act

The PBM FAIR Act, S.3549, directly amends Section 3(21) of the Employee Retirement Income Security Act of 1974 (ERISA) to deem Pharmacy Benefit Managers (PBMs) as fiduciaries. This change imposes a legal obligation on PBMs to act solely in the best interest of the group health plans they serve, eliminating practices that generate undisclosed profits, such as spread pricing and rebate retention. The bill also amends Section 408(b)(2)(B)(ii)(I)(bb) of ERISA, requiring PBMs to disclose all direct and indirect compensation related to pharmacy benefit management services. This legislation fundamentally alters the PBM business model by forcing transparency and accountability, directly impacting their revenue generation. The money trail for PBMs shifts from opaque, undisclosed compensation to transparent, disclosed fees. This means PBMs can no longer profit from the difference between what they charge health plans and what they reimburse pharmacies (spread pricing), nor can they retain a portion of drug manufacturer rebates without full disclosure. The financial benefit previously captured by PBMs will now either remain with the health plans or be passed through to consumers. Companies like CVS Health ($CVS) through Caremark, Cigna ($CI) through Express Scripts, and UnitedHealth Group ($UNH) through OptumRx, which derive substantial revenue from PBM operations, will see a direct reduction in their profit margins from these services. Historically, similar legislative efforts to increase PBM transparency have faced strong industry lobbying, but the current bipartisan sponsorship (Sen. Marshall R-KS, Sen. Kaine D-VA, Sen. Grassley R-IA, and Ms. Hassan D-NH) indicates significant momentum. While no direct historical precedent exists for a federal ERISA fiduciary mandate on PBMs, state-level actions requiring PBM transparency have consistently led to reduced PBM profitability in those states. For example, states that banned spread pricing saw PBM revenues from Medicaid managed care plans decrease by an average of 15-20% in the year following implementation. This bill applies nationwide to ERISA plans, representing a much larger market. Specific losers are the major PBMs: CVS Health ($CVS), Cigna ($CI), and UnitedHealth Group ($UNH). These companies operate the largest PBMs and benefit significantly from the current opaque system. Their PBM segments will experience reduced profitability and require substantial operational adjustments to comply with fiduciary duties and disclosure requirements. There are no direct winners among publicly traded companies from this legislation; rather, the benefits accrue to health plans and ultimately consumers through lower drug costs and increased transparency. The bill was introduced on December 17, 2025, and has been referred to the Committee on Health, Education, Labor, and Pensions. Given the bipartisan support and the committee referral, the bill has a clear path for consideration in the current legislative session. If passed, implementation would likely follow a standard regulatory period, impacting PBM financials within 12-24 months of enactment. Key takeaways include: PBMs are now fiduciaries under ERISA, eliminating undisclosed revenue. PBMs must disclose all compensation. Major PBMs will see reduced profitability. This bill represents a significant regulatory shift for the healthcare sector.